TABLE 1.
Characteristics of the 35 Patients
| Variable | Characteristic | Data |
|---|---|---|
| Age (y) | 57 ± 11 | |
| Sex | Female | 5/35 (14.3) |
| Male | 30/35 (85.7) | |
| Height (cm) | 178 ± 7 | |
| Weight (kg) | 86.8 ± 15.8 | |
| Cardiovascular risk factors | Diabetes | 11/35 (31.4) |
| Arterial hypertension | 19/35 (54.3) | |
| Dyslipidemia | 25/35 (71.4) | |
| Obesity (BMI > 30 kg/m2) | 9/35 (25.7) | |
| Smoking | 21/35 (60.0) | |
| Culprit vessel | LAD | 24/35 (68.6) |
| LCX | 3/35 (8.6) | |
| RCA | 8/35 (22.9) | |
| Symptom to wire time (min) | 234 ± 190 | |
| Peak creatine kinase (U/L) | 3416 ± 3104 | |
| Peak C-reactive protein (mg/L) | 42.6 ± 53.2 | |
| Peak leukocyte count (1,000/mm3) | 14.4 ± 4.4 | |
| Peak creatinine (mg/dL) | 97.1 ± 20.7 | |
| Medication at PET | ASS | 32/35 (91.4) |
| P2Y12 antagonists | 35/35 (100) | |
| OAK | 3/35 (8.5) | |
| Statins | 35/35 (100) | |
| β-blockers | 33/35 (94.3) | |
| Noninsulin glucose- lowering drugs | 11/35 (31.4) | |
| Insulin | 2/35 (5.7) | |
| ACE inhibitors | 22/35 (62.9) | |
| ATII blockers | 13/35 (37.1) |
BMI = body mass index; LAD = left anterior descending coronary artery; LCX = left circumflex coronary artery; RCA = right coronary artery; ASS = aspirin; P2Y12 = the adenosine diphosphate receptor on platelets; OAK = oral anticoagulation; ACE = angiotensin-converting enzyme; ATII = angiotensin 2.
Qualitative data are number and percentage; continuous data are mean ± SD.